We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An investigational oral drug lowered lipoprotein(a) ...
Silence Therapeutics announced positive topline 36-week data from its ongoing phase 2 study of zerlasiran, a long-acting agent directed at lowering Lp(a) levels. In a statement, the company said the ...
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine ...
LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...
Japanese patient cohort enrollment is completed ahead of schedule at multiple clinical sites including the National Cancer Center in Tokyo The incidence rate of never-smokers with non-small cell lung ...
Morning Overview on MSN
Novartis, Amgen, Lilly target Lp(a) in bid for next heart drugs
Statins cannot touch it. Neither can diet or exercise. Lipoprotein(a), a cholesterol-like particle hardwired into a person’s DNA, circulates at elevated levels in roughly one in five adults and raises ...
PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and ...
Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar. We'll be talking in depth today with some of our Lantern's team and also with our collaborator and ...
Lipella Pharmaceuticals Inc. announced positive topline results from the second cohort of its Phase 2a clinical study of LP-310, a liposomal-tacrolimus oral rinse aimed at treating oral lichen planus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results